Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study.

he aim of confirming Atzpodien's data, the same low-dose regimen was used and, in an adequate number of patients (50), our data show a similar response rate. The incidence of response was higher in asymptomatic patients (a well-known prognostic factor in this neoplasia), but this difference did not reach statistical significance, prob- ably because of the limited size of the population.

also in 111,027 other papers